Urelumab alone or in combination with rituximab in patients with relapsed or refractory B‐cell lymphoma

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

(2019) Stephen M. Ansell et al.   JOURNAL OF CLINICAL ONCOLOGY

An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer

(2019) Dinh-Toi Chu et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

(2019) Xinyue Qi et al.   Nature Communications

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy

(2019) Christina Claus et al.   Science Translational Medicine

Follicular lymphoma: 2018 update on diagnosis and management

(2018) Arnold Freedman   AMERICAN JOURNAL OF HEMATOLOGY

Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27–Dependent Pathway

(2018) Todd Bartkowiak et al.   CLINICAL CANCER RESEARCH

S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity

(2018) Jinhua Zhang et al.   OncoImmunology

A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

(2018) Marta Compte et al.   Nature Communications

Non-Hodgkin lymphoma

(2017) James O Armitage et al.   LANCET

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

(2016) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy

(2015) A. Yonezawa et al.   CLINICAL CANCER RESEARCH

Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

(2015) Carla Casulo et al.   JOURNAL OF CLINICAL ONCOLOGY

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy

(2014) Dass S. Vinay et al.   BMB Reports

Diffuse large B-cell lymphoma—treatment approaches in the molecular era

(2013) Mark Roschewski et al.   Nature Reviews Clinical Oncology

Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges

(2013) Kitsada Wudhikarn et al.   Journal of Comparative Effectiveness Research

Targeting Costimulatory Molecules to Improve Antitumor Immunity

(2012) Daria Capece et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Agonist Anti-CD137 mAb Act on Tumor Endothelial Cells to Enhance Recruitment of Activated T Lymphocytes

(2011) A. Palazon et al.   CANCER RESEARCH

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion

(2009) R. Houot et al.   BLOOD

Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

(2009) S. M. Ansell et al.   CLINICAL CANCER RESEARCH